| ￥3000 | |
| Z04171-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized CD21, His, Human at 1μg/ml (100μl/well) on the plate can bind Anti-CD21 Antibody, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 105.3 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 110-130 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized CD21, His, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-CD21 Antibody, hFc Tag with the EC50 of 2.9 ng/ml determined by ELISA. »
The purity of CD21, His, Human is greater than 95% as determined by SEC-HPLC. »
CD21, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | CD21 mRNA expression, an EBV-entry receptor, was transiently detected in NK cells after exosome treatment, and levels decreased after further culture. CD21 protein expression was also transiently transferred to NK cells after co-culture with an EBV-positive Burkitt lymphoma cell line (Raji) via trogocytosis. However, EBV did not infect NK cells through CD21-mediated trogocytosis. |
| Synonyms | EBV receptor; CD21; C3DR; CR2; C3DRSLEB9; CVID7; SLEB9 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
